Cyclobenzaprine
Cyclobenzaprine, sold under several brand names including, historically, Flexeril, is a muscle relaxer used for muscle spasms from musculoskeletal conditions of sudden onset. It is not useful in cerebral palsy. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Flexeril, Amrix, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682514 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 33–55% |
Protein binding | 93% |
Metabolism | major: CYP3A4, CYP1A2; minor: CYP2D6, N-demethylation |
Metabolites | Norcyclobenzaprine |
Elimination half-life | 32 hours (extended-release, range 8–37 hours), 18 hours (immediate release, range 8–37 hours) |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.588 |
Chemical and physical data | |
Formula | C20H21N |
Molar mass | 275.395 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Common side effects include headache, feeling tired, dizziness, and dry mouth. Serious side effects may include an irregular heartbeat. There is no evidence of harm in pregnancy, but it has not been well studied in this population. It must not be used with an MAO inhibitor. How it works is unclear.
Cyclobenzaprine was approved for medical use in the United States in 1977. It is available by prescription as a generic medication. In 2021, it was the 45th most commonly prescribed medication in the United States, with more than 15 million prescriptions. It was not available in the United Kingdom as of 2012.